Immunome, Inc. (IMNM)
NASDAQ: IMNM · Real-Time Price · USD
21.04
+0.09 (0.43%)
At close: Mar 6, 2026, 4:00 PM EST
21.05
+0.01 (0.05%)
After-hours: Mar 6, 2026, 7:51 PM EST
Immunome Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 6.94 | 9.04 | 14.02 | - | - | |
| Revenue Growth (YoY) | -23.23% | -35.50% | - | - | - | |
| Cost of Revenue | 177.29 | 129.54 | 23.09 | 23.11 | - | |
| Gross Profit | -170.35 | -120.5 | -9.07 | -23.11 | - | |
| Selling, General & Admin | 43.77 | 32.96 | 19.66 | 13.79 | 11.09 | |
| Research & Development | - | - | - | - | 14.11 | |
| Operating Expenses | 43.77 | 32.96 | 19.66 | 13.79 | 25.2 | |
| Operating Income | -214.11 | -153.46 | -28.73 | -36.9 | -25.2 | |
| Interest Expense | - | - | - | - | -0.01 | |
| Interest & Investment Income | 11.72 | 12.84 | 2.72 | 0.01 | - | |
| EBT Excluding Unusual Items | -202.39 | -140.62 | -26 | -36.9 | -25.21 | |
| Other Unusual Items | - | - | - | - | 0.5 | |
| Pretax Income | -212.39 | -292.96 | -106.81 | -36.9 | -24.71 | |
| Net Income | -212.39 | -292.96 | -106.81 | -36.9 | -24.71 | |
| Preferred Dividends & Other Adjustments | - | - | - | 0.62 | - | |
| Net Income to Common | -212.39 | -292.96 | -106.81 | -37.52 | -24.71 | |
| Shares Outstanding (Basic) | 87 | 59 | 20 | 12 | 12 | |
| Shares Outstanding (Diluted) | 87 | 59 | 20 | 12 | 12 | |
| Shares Change (YoY) | 48.96% | 195.51% | 63.64% | 5.10% | 240.41% | |
| EPS (Basic) | -2.43 | -5.00 | -5.38 | -3.09 | -2.14 | |
| EPS (Diluted) | -2.43 | -5.00 | -5.38 | -3.09 | -2.14 | |
| Free Cash Flow | -200.6 | -117.97 | -8.4 | -28.94 | -18.31 | |
| Free Cash Flow Per Share | -2.30 | -2.01 | -0.42 | -2.39 | -1.59 | |
| Gross Margin | - | - | -64.71% | - | - | |
| Operating Margin | -3084.76% | -1697.33% | -204.94% | - | - | |
| Profit Margin | -3059.99% | -3240.38% | -761.92% | - | - | |
| Free Cash Flow Margin | -2890.13% | -1304.80% | -59.92% | - | - | |
| EBITDA | -211.65 | -151.89 | -28.27 | -36.48 | -24.45 | |
| EBITDA Margin | - | - | -201.68% | - | - | |
| D&A For EBITDA | 2.47 | 1.57 | 0.46 | 0.42 | 0.76 | |
| EBIT | -214.11 | -153.46 | -28.73 | -36.9 | -25.2 | |
| EBIT Margin | - | - | -204.94% | - | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.